Challenges in DPYD Test Implementation in Patients Treated with Fluoropyrimidines are DPYD Genotype Arriving on Time? [Letter]

Click to increase image sizeClick to decrease image size

View responses to this article:

Response to: “Challenges in DPYD Test Implementation in Patients Treated with Fluoropyirimidines, is DPYD Genotype Arriving on Time?” [Response to Letter]

Disclosure

Dr Mónica Guillot Morales reports non-financial support from Servier, non-financial support from Amgen, non-financial support from Roche, non-financial support from Merck, outside the submitted work. The authors report no other conflicts of interest in this communication.